Digirad wins solid-state detector patent
Solid-state gamma camera developer Digirad of San Diego announced this month that the U.S. Patent Office has granted the company a patent on a method of manufacturing solid-state digital detector modules. Digirad believes the patent is so comprehensive
Solid-state gamma camera developer Digirad of San Diego announced this month that the U.S. Patent Office has granted the company a patent on a method of manufacturing solid-state digital detector modules. Digirad believes the patent is so comprehensive that it will be difficult for other potential solid-state detector manufacturers to avoid infringement.
The patent covers technology that uses semiconductor gamma ray detector modules that can be butted on all sides to form a seamless imaging array of any size. The patent also covers gamma cameras that use these modules, according to the company.
Digirad is unaware of any commercially feasible way to manufacture a solid-state, large field-of-view gamma camera without violating the patent, because solid-state cameras require individual detectors that must be tiled together, rather than a single crystal as used in vacuum-tube systems, according to Karen Klause, president and CEO. Klause declined to comment on whether Digirad would license the buttable module technology.
Digirad manufactures and markets Digirad 2020 TC Imager, a portable single-head gamma camera that uses solid-state detector technology.
New MRI Research Explores Links Between Waist-to-Hip Ratio and Memory in Aging
March 13th 2025Researchers found that a higher waist-to-hip ratio in midlife was associated with higher mean diffusivity in 26 percent of total white matter tracts in the cingulum as well as the superior and inferior longitudinal fasciculus.
Can Ultrasound-Based Radiomics Enhance Differentiation of HER2 Breast Cancer?
March 11th 2025Multicenter research revealed that a combined model of clinical factors and ultrasound-based radiomics exhibited greater than a 23 percent higher per patient-level accuracy rate for identifying HER2 breast cancer than a clinical model.
